Patrys Limited (AU:PAB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Patrys Limited reports a delay in the GMP manufacturing run of its cancer-targeting antibody drug PAT-DX1, due to a process inconsistency in specification testing at their Contract Development Manufacturing Organization. The issue is being addressed, with testing and potential drug release for clinical trials now expected in the second half of August 2024. This setback impacts the timeline for initiating clinical development for PAT-DX1, a promising treatment for various cancers.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
